2-(2-cyclohexylethyl)phenol | 63623-72-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2-(2-cyclohexylethyl)phenol
• 英文别名: 2-Cyclohexylethylphenol
• CAS: 63623-72-3
• 化学式: C₁₄H₂₀O
• 分子量: 204.312
• InChiKey: HOJFCSFTGYXBFC-UHFFFAOYSA-N

物化性质

• 沸点：
  170-174 °C(Press: 10 Torr)
• 密度：
  1.005±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(2-cyclohexylethyl)phenol 在 三氯化铝 、 sodium hydride 作用下， 生成 1-[3-(2-Cyclohexyl-ethyl)-4-(2-diethylamino-ethoxy)-phenyl]-ethanone
  参考文献：
  名称：

  Compounds with gastric antisecretory activity. 1. Phenoxyalkylamines

  摘要：

  A series of 0-alkylphenoxyalkylamines, derived from classical H1 antagonists, has been found to inhibit histamine-induced gastric acid secretion. The most potent compound was trans-1-[2[2-[2-(1-adamantyl)vinyl] phenoxy] ethyl]pyrrolidine (54). The 0-acylphenol 23 required for the preparation of 54 was obtained by the novel reaction of 1-bromoadamantane (21) with 4-hydroxycoumarin (20) using diethyl phosphonate as solvent. The product 22 was then hydrolyzed under basic conditions to give 23 in high yield. 54 was not an H2 antagonist and its mode of action remains unknown. The compound had no significant anticholinergic, antiinflammatory, anticonvulsant, sedative, or H1-antihistaminic activity.

  DOI：

  10.1021/jm00220a018
• 作为产物：
  描述：

  α-(1-Oxy-2-cyclohexylethyl)-anisol 在 palladium on activated charcoal 盐酸 、 氢气 、 吡啶盐酸盐 作用下， 生成 2-(2-cyclohexylethyl)phenol
  参考文献：
  名称：

  Compounds with gastric antisecretory activity. 1. Phenoxyalkylamines

  摘要：

  A series of 0-alkylphenoxyalkylamines, derived from classical H1 antagonists, has been found to inhibit histamine-induced gastric acid secretion. The most potent compound was trans-1-[2[2-[2-(1-adamantyl)vinyl] phenoxy] ethyl]pyrrolidine (54). The 0-acylphenol 23 required for the preparation of 54 was obtained by the novel reaction of 1-bromoadamantane (21) with 4-hydroxycoumarin (20) using diethyl phosphonate as solvent. The product 22 was then hydrolyzed under basic conditions to give 23 in high yield. 54 was not an H2 antagonist and its mode of action remains unknown. The compound had no significant anticholinergic, antiinflammatory, anticonvulsant, sedative, or H1-antihistaminic activity.

  DOI：

  10.1021/jm00220a018

文献信息

• [2-(.OMEGA.-Phenylakyl)phenoxy]alkylamines. II. Synthesis and Selective Serotonin-2 Receptor Binding.
  作者：Naoki TANAKA、Riki GOTO、Miho HAYAKAWA、Atsuhiro SUGIDACHI、Taketoshi OGAWA、Fumitoshi ASAI、Koichi FUJIMOTO

  DOI：10.1248/cpb.48.245

  日期：——

  A series of [2-(ω-phenylalkyl)phenoxy]alkylamines was synthesized and thir receptor binding affinity was examined in vitro. These compounds showed an affinity for serotonin-2 (5-HT2) and dopamine-2 (D2) receptors. [2-(2-phenylethyl)phenoxy]alkylamine derivatives with a pyrrolidine or piperidine moiety in the structure showed higher affinity for 5-HT2 receptors but lower affinity for D2 receptors. Among these compounds, (S)-2-[2-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]ethyl]1-methylpyrrolidine, (S)-27, exhibited the most potent and selective affinity for 5-HT2 receptors. Furthermore, (S)-27 was effective in inhibiting 5-HT-induced vasoconstriction in vitro and platelet aggregation both in vitro and ex vivo.

  合成了一系列[2-(ω-苯基烷基)苯氧]烷基胺，并在体外检测了它们的受体结合亲和力。这些化合物显示出对血清素-2（5-HT2）和多巴胺-2（D2）受体的亲和力。在结构中含有吡咯烷或哌啶基团的[2-(2-苯乙基)苯氧]烷基胺衍生物对5-HT2受体表现出更高的亲和力，但对D2受体的亲和力较低。在这些化合物中，(S)-2-[2-[2-[2-(3-甲氧基苯基)乙基]苯氧]乙基]1-甲基吡咯烷（(S)-27）显示出对5-HT2受体最具效力和选择性的亲和力。此外，(S)-27在体外有效抑制了5-HT引起的血管收缩和血小板聚集，无论是体外还是离体实验中均表现出了效果。
• Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these
  申请人：Nishi Takahide

  公开号：US20050043386A1

  公开（公告）日：2005-02-24

  Amino alcohol compounds and phosphonic acid compounds having excellent immunosuppressive activity, pharmacologically acceptable salts thereof and pharmacologically acceptable esters thereof, and pharmaceutical compositions comprising such compounds, the compounds having the following formula: wherein R 1 and R 2 each represent hydrogen, or a protecting group of the amino group; R 3 represents hydrogen, or a protecting group of the hydroxyl group; R 4 represents a lower alkyl group; n is 1 to 6; X represents oxygen or nitrogen, which is unsubstituted or substituted with a lower alkyl group; Y represents ethylene; Z represents a C 1 -C 10 alkylene; R 5 represents an aryl group; and R 6 and R 7 each represents hydrogen; provided that when R 5 represents hydrogen, then Z represents a group other than a single bond or a straight chain C 1 -C 10 alkylene group.

  具有出色的免疫抑制活性的氨基醇化合物和膦酸化合物，其药理学上可接受的盐和药理学上可接受的酯，以及包含这些化合物的制药组合物，其中化合物具有以下式子：其中R1和R2各代表氢，或氨基保护基；R3代表氢，或羟基保护基；R4代表较低的烷基；n为1至6；X代表氧或氮，未取代或取代为较低的烷基；Y代表乙烯；Z代表C1-C10烷基；R5代表芳基；R6和R7各代表氢；但是当R5代表氢时，Z代表除单键或直链C1-C10烷基组以外的一种基团。
• Amino alcohol compounds
  申请人：Nishi Takahide

  公开号：US20070105933A1

  公开（公告）日：2007-05-10

  A method for the preventing a disease selected from the group consisting of rheumatoid arthritis and psoriasis in a mammal, such as a human, in need thereof, which includes administering to the mammal a pharmaceutically effective amount of a compound of formula (Ia) wherein R 1 and R 2 are each hydrogen; R 3 is hydrogen; R 4 is C 1 -C 2 alkyl; n is 2; X is=N-D, wherein D is hydrogen, C 1 -C 4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH 2 or phenylene; Z is ethylene or trimethylene; R 5 is an unsubstituted C 3 -C 10 cycloalkyl, an unsubstituted C 6 -C 10 aryl, or a C 3 -C 10 cycloalkyl or C 6 -C 10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R 6 and R 7 are each hydrogen.

  本发明涉及一种用于预防哺乳动物，例如人类，需要预防风湿性关节炎和银屑病等疾病的方法，包括向哺乳动物内部给予化合物（Ia）的药物有效量，其中R1和R2均为氢; R3为氢; R4为C1-C2烷基; n为2; X为=N-D，其中D为氢、C1-C4烷基或苯基; Y为乙烯基、乙炔基、-CO-CH2或苯基; Z为乙烯基或三亚甲基; R5为未取代的C3-C10环烷基、未取代的C6-C10芳基或取代有1-3个取代基的C3-C10环烷基或C6-C10芳基，所述取代基选自卤素、低碳基、卤代低碳基和低烷氧基的群体; R6和R7均为氢。
• Method for treating a immunology-related disease
  申请人：Nishi Takahide

  公开号：US20090326038A1

  公开（公告）日：2009-12-31

  A method for treating an immunology-related disease. The method involves administering to a mammal in need thereof a pharmaceutically effective amount of an amino acid compound, a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof. The compound has the following formula: , wherein R 1 and R 2 are each hydrogen; R 3 is hydrogen; R 4 is C 1 -C 2 alkyl; n is 2; X is ═N-D, wherein D is hydrogen, C 1 -C 4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH 2 or phenylene; Z is ethylene or trimethylene; R 5 is unsubstituted C 3 -C 10 cycloalkyl, unsubstituted C 3 -C 10 aryl, or C 3 -C 10 cycloalkyl or C 6 -C 10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R 6 and R 7 are each hydrogen.

  一种治疗免疫相关疾病的方法。该方法涉及向需要治疗的哺乳动物中注射药物有效量的氨基酸化合物，其药理学上可接受的盐或其药理学上可接受的酯。该化合物具有以下式子：其中R1和R2均为氢；R3为氢；R4为C1-C2烷基；n为2；X为═N-D，其中D为氢、C1-C4烷基或苯基；Y为乙烯、乙炔基、—CO—CH2或苯基；Z为乙烯或三亚甲基；R5为未取代的C3-C10环烷基、未取代的C3-C10芳基或取代有1至3个卤素、低烷基、卤代低烷基和低烷氧基的C3-C10环烷基或C6-C10芳基；R6和R7均为氢。
• Amino alcohol compounds or phosphonic acid derivatives thereof
  申请人：Nishi Takahide

  公开号：US20070142335A1

  公开（公告）日：2007-06-21

  A method for the prevention or treatment of an immunology-related disease, which is not rheumatoid arthritis or psoriasis, in a mammal in need thereof which involves administering to the mammal a pharmaceutically effective amount of a compound, a pharmacologically acceptable salt of the compound or a pharmacologically acceptable ester of the compound, wherein the compound is a compound having a formula (Ia): wherein R 1 and R 2 are each a hydrogen, R 3 is hydrogen; R 4 is C 1 -C 2 alkyl; n is 2; X is ═N-D, wherein D is hydrogen C 1 -C 4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH 2 or phenylene; Z is ethylene or trimethylene; R 5 is an unsubstituted C 3 -C 10 cycloalkyl, an unsubstituted C 6 -C 10 aryl, or a C 3 -C 10 cycloalkyl or a C 6 -C 10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R 6 and R 7 are each hydrogen.

  一种用于预防或治疗非类风湿性关节炎或牛皮癣等免疫相关疾病的方法，涉及向需要治疗的哺乳动物中投与一种化合物的药物有效量，该化合物的药物学上可接受的盐或酯，其中该化合物具有公式(Ia)：其中R1和R2均为氢，R3为氢；R4为C1-C2烷基；n为2；X为═N-D，其中D为氢、C1-C4烷基或苯基；Y为乙烯、乙炔、—CO—CH2或苯基；Z为乙烯或三亚甲基；R5为未取代的C3-C10环烷基、未取代的C6-C10芳基，或取代有1至3个卤素、低烷基、卤代低烷基和低烷氧基的C3-C10环烷基或C6-C10芳基；R6和R7均为氢。